Reduced levels of transforming growth factor β receptor type II in human prostate cancer: An immunohistochemical study

Russel H. Williams, Alan M.F. Stapleton, Guang Yang, Luan Truong, Eammon Rogers, Terry L. Timme, Thomas M. Wheeler, Peter T. Scardino, Timothy C. Thompson

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

In previous studies we demonstrated that the growth of human prostatic adenocarcinoma is associated with aberrant accumulation of transforming growth factor (TGF) β1, a growth factor that has been shown to be a potent inhibitor of epithelial cell proliferation. We investigated the expression of TGF-β receptor II (TGFβR-II) in benign prostate tissue and in prostate cancer using standard immunohistochemical techniques. Quantitation of immunopositivity for TGFβR-II was assessed on a visual analogue scale ranging from 0 (absence of staining) to 4+ (intensely positive staining). All of the benign glandular epithelia stained intensely, either 3+ or 4+, representative of the ubiquitous nature of TGFβR-II in normal tissue Overall, staining was reduced in prostate cancer sections, and there was progressively diminished staining as the histological grade of the cancer increased (P < 0.01, Kruskal-Wallis test). This immunohistochemical study indicates that a decline in the levels of TGFβR-II is correlated with advancing histological aggressiveness of the cancer and suggests that aberrant TGFβR-II function may play a role in human prostate carcinogenesis.

Original languageEnglish (US)
Pages (from-to)635-640
Number of pages6
JournalClinical Cancer Research
Volume2
Issue number4
StatePublished - Apr 1996

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Reduced levels of transforming growth factor β receptor type II in human prostate cancer: An immunohistochemical study'. Together they form a unique fingerprint.

Cite this